EARLY BREAST CANCER

This study is testing if a combination of two hormone therapy drugs (letrozole and abemaciclib) works as well as or better than standard chemotherapy when given before surgery for certain types of early-stage breast cancer. It involves about 200 women whose cancer is hormone-sens…

This large, late-stage study is testing whether a new oral medication called giredestrant works better than the doctor's choice of standard hormone therapy at preventing cancer from returning after surgery. It involves over 4,000 people with early-stage, hormone-sensitive breast …

This large, late-stage trial is testing whether adding a drug called ribociclib to standard hormone therapy can better prevent cancer from returning in people with a common type of early-stage breast cancer. It enrolled over 5,000 men and women who had surgery and are at higher r…

This study aimed to compare a new version of the cancer drug pertuzumab (called EG1206A) with the original version (Perjeta) for treating early-stage HER2-positive breast cancer. Patients would have received the drug along with standard chemotherapy and another targeted therapy b…

This study is testing whether some patients with early-stage, HER2-positive breast cancer can be successfully treated without chemotherapy. It uses a combination of targeted antibody drugs given as an injection under the skin. The treatment plan is adjusted after surgery based on…

This study is testing a new, potentially gentler combination of chemotherapy drugs given before surgery for early-stage HER2-positive breast cancer. It aims to see if this less toxic treatment works as well as the current standard by measuring if it completely removes the cancer.…

This study investigates whether young women with hormone-sensitive early breast cancer can safely pause their hormone-blocking therapy to try to become pregnant. It follows over 500 participants to see if this treatment break increases the risk of the cancer coming back. The rese…